As suggested, PPARs are nuclear receptors with an array of diverse regulatory functions including metabolic and inflammatory coordination, and regulation of fibrogenesis.20 In preclinical models, the indole-sulfonamide derivative, lanifibranor (IVA337), a pan-PPAR agonist, improved insulin sensitivity and macrophage activation, with consequent reduction in liver fibrosis and inflammatory gene expression with higher efficacy than single or dual PPAR agonists.20,21. Here, PPARA is linked to Hepatic fibrosis.